Advanced

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Santini, Valeria; Prebet, Thomas; Fenaux, Pierre; Gattermann, Norbert; Nilsson, Lars LU ; Pfeilstöcker, Michael; Vyas, Paresh and List, Alan F (2014) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 38(12). p.1381-1391
Abstract
In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
volume
38
issue
12
pages
1381 - 1391
publisher
Elsevier
external identifiers
  • pmid:25444075
  • wos:000345614400001
  • scopus:84915785597
ISSN
1873-5835
DOI
10.1016/j.leukres.2014.09.008
language
English
LU publication?
yes
id
bf927246-059e-434c-9dd2-f300f2e374cb (old id 4913438)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25444075?dopt=Abstract
date added to LUP
2015-01-08 14:52:37
date last changed
2017-10-22 03:31:31
@article{bf927246-059e-434c-9dd2-f300f2e374cb,
  abstract     = {In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.},
  author       = {Santini, Valeria and Prebet, Thomas and Fenaux, Pierre and Gattermann, Norbert and Nilsson, Lars and Pfeilstöcker, Michael and Vyas, Paresh and List, Alan F},
  issn         = {1873-5835},
  language     = {eng},
  number       = {12},
  pages        = {1381--1391},
  publisher    = {Elsevier},
  series       = {Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis},
  title        = {Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.},
  url          = {http://dx.doi.org/10.1016/j.leukres.2014.09.008},
  volume       = {38},
  year         = {2014},
}